The global BCL B cell lymphoma inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). BCL-2, also known as B Cell Lymphoma 2, is a protein-encoding gene belonging to the B cell lymphoma family. The market growth is majorly attributable to the growth in the prevalence of diffuse B cell lymphoma, a common type of non-Hodgkin lymphoma. For instance, according to an article by Lymphoma Research Foundation in 2019, in the US, DLBCL accounted for 22% of newly diagnosed B cell lymphoma cases. Around 18,000 people globally are diagnosed with DLBCL each year. 

Adding to this, the disease affects people over 60 years of age. According to the American Cancer Society in 2019, an estimated 20,720 people were diagnosed with chronic lymphocytic lymphoma. Moreover, 90% of the people diagnosed with this form of lymphoma are estimated to affect people above 50 years of age. In the US, 2,220 men and 1,710 women are expected to be suffering from chronic lymphocytic lymphoma every year. Moreover, as per the American Cancer Society, about 3,930 mortalities were anticipated to take place in 2019. 

Further, there are various inhibitor drugs being approved in the market that spur market growth. For instance, Venetoclax is the only and first approved FDA BCL-2 inhibitor drug for chronic lymphocytic lymphoma patients. Although various clinical trials are being carried out for the development of new BCL-2 inhibitors.

Some key players operating in the market include AbbVie, Roche, Abcam, Biorbyt, Biovison, and Tocris Bioscience. These players are eyeing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape:  AbbVie, Roche, Abcam, Biorbyt, Biovison, and Tocris Bioscience

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global BCL B Cell Lymphoma Inhibitors Market - Segmentation

By Therapy 

• Monotherapy

• Combination Therapy

By Type

• Positive Lymphoma

• Follicular Lymphoma

Global BCL B Cell Lymphoma Inhibitors Market Segmentation by Region